Fundraising FoxPhoreMost
Cambridge, GB · 12 known investors
Find your way into PhoreMost
Sign up to see every warm intro you have to PhoreMost
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PhoreMost team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
Investors · 12
How we know: Amadeus Capital Partners's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Astellas Venture Management LLC's portfolio page · tech.eu · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Cambridge Angels group's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: University of Cambridge Enterprise's portfolio page · Not right? Tell us
How we know: press coverage · funding news · Not right? Tell us
How we know: tech.eu · Not right? Tell us
How we know: a partner's Signal profile · amadeuscapital.com · Not right? Tell us
Also in the syndicate · 5
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BSep 2024 · 4 sources
BGF (lead), Parkwalk Advisors (lead), Astellas Venture Management, Morningside Ventures, o2h ventures, Trend Investment Group, XtalPi Inc, XtalPi Inc.
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does PhoreMost do?
- PhoreMost is a biotechnology company developing small molecule drugs and targeted protein degradation therapeutics for cancers with high unmet clinical need, with a lead program (PMC-001) for primary and metastatic brain cancers in Phase 1/2a clinical evaluation.
- Who are PhoreMost's investors?
- PhoreMost's investors include Amadeus Capital Partners, Astellas Venture Management LLC, Cambridge Angels group, University of Cambridge Enterprise, Amadeus Capital SA, O2h Ventures, Parkwalk Advisors.
- Where is PhoreMost headquartered?
- PhoreMost is headquartered in Cambridge, GB.